Alnylam Pharmaceuticals, Inc. $ALNY Shares Purchased by National Pension Service

National Pension Service raised its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 7.9% in the 2nd quarter, HoldingsChannel reports. The fund owned 198,295 shares of the biopharmaceutical company’s stock after acquiring an additional 14,506 shares during the period. National Pension Service’s holdings in Alnylam Pharmaceuticals were worth $59,693,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the business. California State Teachers Retirement System boosted its stake in Alnylam Pharmaceuticals by 30,461.4% in the 2nd quarter. California State Teachers Retirement System now owns 60,164,157 shares of the biopharmaceutical company’s stock worth $18,111,216,000 after buying an additional 59,967,294 shares during the last quarter. Norges Bank acquired a new position in shares of Alnylam Pharmaceuticals during the 4th quarter valued at about $895,816,000. Legal & General Group Plc acquired a new stake in shares of Alnylam Pharmaceuticals in the second quarter worth approximately $278,321,000. Qube Research & Technologies Ltd purchased a new stake in Alnylam Pharmaceuticals in the third quarter valued at approximately $369,943,000. Finally, AQR Capital Management LLC increased its position in Alnylam Pharmaceuticals by 295.2% during the third quarter. AQR Capital Management LLC now owns 744,008 shares of the biopharmaceutical company’s stock worth $336,009,000 after purchasing an additional 555,759 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Up 0.5%

Shares of NASDAQ ALNY opened at $248.68 on Friday. The stock has a fifty day moving average price of $254.43 and a 200 day moving average price of $288.99. The company has a current ratio of 3.05, a quick ratio of 2.99 and a debt-to-equity ratio of 0.75. Alnylam Pharmaceuticals, Inc. has a 12-month low of $197.81 and a 12-month high of $495.55. The company has a market cap of $33.28 billion, a P/E ratio of 46.22 and a beta of 0.31.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, topping the consensus estimate of $1.63 by $0.21. The company had revenue of $1.29 billion during the quarter, compared to the consensus estimate of $1.32 billion. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The company’s revenue was up 66.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.51) earnings per share. Research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 6.71 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently issued reports on ALNY shares. TD Cowen reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, August 31st. Wall Street Zen cut Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 2nd. Weiss Ratings upgraded Alnylam Pharmaceuticals from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, July 31st. Truist Financial cut their price objective on Alnylam Pharmaceuticals from $410.00 to $315.00 and set a “buy” rating on the stock in a report on Tuesday, August 4th. Finally, Raymond James Financial raised Alnylam Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a $420.00 price objective on the stock in a research note on Monday, August 3rd. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $376.67.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi) technology. RNAi therapies are designed to silence specific genes involved in disease, offering a way to target conditions that may be difficult to treat with conventional drug approaches. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam’s commercial products include Onpattro (patisiran), Givlaari (givosiran), Oxlumo (lumasiran) and Amvuttra (vutrisiran).